Cargando…

Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial

Objective: Metabolic syndrome is a potential side effect of atypical antipsychotics which are the current standard treatment for schizophrenia. Therefore, we aimed to examine the effect of barberry root (Berberis vulgaris) on the prevention of metabolic syndrome caused by atypical antipsychotic drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Rostami, Hamzeh, Babaali, Farzaneh, Moradi, Leila, Golfakhrabadi, Fereshteh, Abdi, Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Psychiatry & Psychology Research Center, Tehran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422947/
https://www.ncbi.nlm.nih.gov/pubmed/37575603
http://dx.doi.org/10.18502/ijps.v18i3.13015
_version_ 1785089338562838528
author Rostami, Hamzeh
Babaali, Farzaneh
Moradi, Leila
Golfakhrabadi, Fereshteh
Abdi, Leila
author_facet Rostami, Hamzeh
Babaali, Farzaneh
Moradi, Leila
Golfakhrabadi, Fereshteh
Abdi, Leila
author_sort Rostami, Hamzeh
collection PubMed
description Objective: Metabolic syndrome is a potential side effect of atypical antipsychotics which are the current standard treatment for schizophrenia. Therefore, we aimed to examine the effect of barberry root (Berberis vulgaris) on the prevention of metabolic syndrome caused by atypical antipsychotic drugs in patients with schizophrenia. Method : Our research was a three-blind randomized clinical trial. The participants included all patients who were diagnosed with schizophrenia through the SCID-5 questionnaire and based on the DSM-5-TR criteria by two psychiatric experts. These patients were randomly divided into intervention and placebo groups. During a three-month treatment period, the intervention group received three 500 mg capsules of barberry root extract daily, whereas the placebo group received the same capsules containing 500 mg of starch powder. Metabolic syndrome variables including fasting blood glucose, serum lipids (triglyceride and cholesterol), blood pressure, weight and waist circumference were measured before and after the treatment as outcome measure. Chi-square and t-tests were used for data analysis using SPSS-22 software. Results: At the beginning of the study, there was no significant difference between the intervention group (n = 41) and the placebo group (n = 47) in terms of demographic factors, and pre-treatment assessments including weight, waist size, fasting blood HDL, fasting blood triglycerides and systolic and diastolic blood pressure and fasting blood glucose (P > 0.05). Within group analysis showed that some metabolic factors significantly increased in both groups after the treatment (P < 0.05). Indeed, in both groups, metabolic syndrome measures worsened after the three-month treatment period. The parameters of weight and waist size were significantly higher in the intervention group than the placebo group after treatment (P < 0.05). Conclusion: Barberry root extract was not able to control the Effects of antipsychotic drugs on metabolic syndrome in schizophrenia.
format Online
Article
Text
id pubmed-10422947
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Psychiatry & Psychology Research Center, Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-104229472023-08-13 Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial Rostami, Hamzeh Babaali, Farzaneh Moradi, Leila Golfakhrabadi, Fereshteh Abdi, Leila Iran J Psychiatry Short Communication Objective: Metabolic syndrome is a potential side effect of atypical antipsychotics which are the current standard treatment for schizophrenia. Therefore, we aimed to examine the effect of barberry root (Berberis vulgaris) on the prevention of metabolic syndrome caused by atypical antipsychotic drugs in patients with schizophrenia. Method : Our research was a three-blind randomized clinical trial. The participants included all patients who were diagnosed with schizophrenia through the SCID-5 questionnaire and based on the DSM-5-TR criteria by two psychiatric experts. These patients were randomly divided into intervention and placebo groups. During a three-month treatment period, the intervention group received three 500 mg capsules of barberry root extract daily, whereas the placebo group received the same capsules containing 500 mg of starch powder. Metabolic syndrome variables including fasting blood glucose, serum lipids (triglyceride and cholesterol), blood pressure, weight and waist circumference were measured before and after the treatment as outcome measure. Chi-square and t-tests were used for data analysis using SPSS-22 software. Results: At the beginning of the study, there was no significant difference between the intervention group (n = 41) and the placebo group (n = 47) in terms of demographic factors, and pre-treatment assessments including weight, waist size, fasting blood HDL, fasting blood triglycerides and systolic and diastolic blood pressure and fasting blood glucose (P > 0.05). Within group analysis showed that some metabolic factors significantly increased in both groups after the treatment (P < 0.05). Indeed, in both groups, metabolic syndrome measures worsened after the three-month treatment period. The parameters of weight and waist size were significantly higher in the intervention group than the placebo group after treatment (P < 0.05). Conclusion: Barberry root extract was not able to control the Effects of antipsychotic drugs on metabolic syndrome in schizophrenia. Psychiatry & Psychology Research Center, Tehran University of Medical Sciences 2023-07 /pmc/articles/PMC10422947/ /pubmed/37575603 http://dx.doi.org/10.18502/ijps.v18i3.13015 Text en Copyright © 2023 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Short Communication
Rostami, Hamzeh
Babaali, Farzaneh
Moradi, Leila
Golfakhrabadi, Fereshteh
Abdi, Leila
Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
title Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
title_full Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
title_fullStr Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
title_full_unstemmed Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
title_short Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
title_sort evaluation of the effect of barberry root (berberis vulgaris) on the prevention of metabolic syndrome caused by atypical antipsychotic drugs in patients with schizophrenia: a three-blind placebo-controlled clinical trial
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422947/
https://www.ncbi.nlm.nih.gov/pubmed/37575603
http://dx.doi.org/10.18502/ijps.v18i3.13015
work_keys_str_mv AT rostamihamzeh evaluationoftheeffectofbarberryrootberberisvulgarisonthepreventionofmetabolicsyndromecausedbyatypicalantipsychoticdrugsinpatientswithschizophreniaathreeblindplacebocontrolledclinicaltrial
AT babaalifarzaneh evaluationoftheeffectofbarberryrootberberisvulgarisonthepreventionofmetabolicsyndromecausedbyatypicalantipsychoticdrugsinpatientswithschizophreniaathreeblindplacebocontrolledclinicaltrial
AT moradileila evaluationoftheeffectofbarberryrootberberisvulgarisonthepreventionofmetabolicsyndromecausedbyatypicalantipsychoticdrugsinpatientswithschizophreniaathreeblindplacebocontrolledclinicaltrial
AT golfakhrabadifereshteh evaluationoftheeffectofbarberryrootberberisvulgarisonthepreventionofmetabolicsyndromecausedbyatypicalantipsychoticdrugsinpatientswithschizophreniaathreeblindplacebocontrolledclinicaltrial
AT abdileila evaluationoftheeffectofbarberryrootberberisvulgarisonthepreventionofmetabolicsyndromecausedbyatypicalantipsychoticdrugsinpatientswithschizophreniaathreeblindplacebocontrolledclinicaltrial